Matches in SemOpenAlex for { <https://semopenalex.org/work/W2281113657> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2281113657 endingPage "662" @default.
- W2281113657 startingPage "662" @default.
- W2281113657 abstract "662 Background: Oxaliplatin and irinotecan in combination with 5-fluorouracil and leucovorin for metastatic colorectal cancer (mCRC) accepted as the standard treatment. There is no standard treatment approach for patients after progression with these agents. In this study aimed to evaluate the efficacy and side effects of patients with previously treated metastatic colorectal cancer a salvage combination with oral 5-fluorouracil (tegafur-uracil UFT) or Mitomycin C and Raltitrexed. Methods: In the 7 centers, data of 62 patients who received Raltitrexed 2.6 mg/m2 (max. 5 mg) (day 1) and UFT 500 mg/day (1-14. days), or Mitomycin C 6mg/m2 (day 1) every 3 weeks, with a diagnosis of metastatic colorectal cancer, between December 2008 and June 2013 has been analyzed retrospectively. Overall survival (OS), progression-free survival (PFS), and toxicity profiles were evaluated. Results: The median age of patients was 51 (min-max: 18-76 years), and 35 (56%) were male and 27 (44%) were female. Thirty nine patients (63%) had ECOG performance status 0 and 1. Four patients (10%) received a combination of UFT and Raltitrexed at the second line and 38 patients (90%) had third, fourth, and fifth lines. Otherwise Mitomycin C plus Raltitrexed protocol used at the second and third lines. Twelve patients (19%) developed grade 3/4 toxicities as diarrhea and fatigue and 13 patients (21%) needed to dose reduction. In all patients the median PFS was 3 months (%95 CI, 2,65–3,34) and the median OS was 6 months (%95 CI, 2,09–9,90). Two groups were evaluated separately; the median PFS was 3 months (%95 CI, 2,60–3,39) and median OS was 6 months (%95 CI, 2,47–9,53) in UFT arm and, the median PFS was 3 months (%95 CI, 1,64–4,35) and median OS was 12 months (%95 CI, 2,83–21,1) in Mitomycin C arm. Statistical significance could not be determined (p>0.05). Conclusions: Thecombination of Raltitrexed with UFT and Mitomycin C showed an acceptable survival time and toxicity in the treatment of patients with previously treated mCRC. It could be considered as a salvage treatment option in mCRC." @default.
- W2281113657 created "2016-06-24" @default.
- W2281113657 creator A5000554665 @default.
- W2281113657 creator A5002839209 @default.
- W2281113657 creator A5007948653 @default.
- W2281113657 creator A5008706516 @default.
- W2281113657 creator A5009438753 @default.
- W2281113657 creator A5021114623 @default.
- W2281113657 creator A5037670666 @default.
- W2281113657 creator A5045696675 @default.
- W2281113657 creator A5059161432 @default.
- W2281113657 creator A5062129196 @default.
- W2281113657 creator A5075330567 @default.
- W2281113657 creator A5080580069 @default.
- W2281113657 creator A5083864092 @default.
- W2281113657 creator A5086747983 @default.
- W2281113657 date "2014-01-20" @default.
- W2281113657 modified "2023-10-16" @default.
- W2281113657 title "Efficacy and safety of raltitrexed combinations with uracil-tegafur or Mitomycin C as salvage treatment in advanced colorectal cancer patients." @default.
- W2281113657 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.662" @default.
- W2281113657 hasPublicationYear "2014" @default.
- W2281113657 type Work @default.
- W2281113657 sameAs 2281113657 @default.
- W2281113657 citedByCount "0" @default.
- W2281113657 crossrefType "journal-article" @default.
- W2281113657 hasAuthorship W2281113657A5000554665 @default.
- W2281113657 hasAuthorship W2281113657A5002839209 @default.
- W2281113657 hasAuthorship W2281113657A5007948653 @default.
- W2281113657 hasAuthorship W2281113657A5008706516 @default.
- W2281113657 hasAuthorship W2281113657A5009438753 @default.
- W2281113657 hasAuthorship W2281113657A5021114623 @default.
- W2281113657 hasAuthorship W2281113657A5037670666 @default.
- W2281113657 hasAuthorship W2281113657A5045696675 @default.
- W2281113657 hasAuthorship W2281113657A5059161432 @default.
- W2281113657 hasAuthorship W2281113657A5062129196 @default.
- W2281113657 hasAuthorship W2281113657A5075330567 @default.
- W2281113657 hasAuthorship W2281113657A5080580069 @default.
- W2281113657 hasAuthorship W2281113657A5083864092 @default.
- W2281113657 hasAuthorship W2281113657A5086747983 @default.
- W2281113657 hasConcept C121608353 @default.
- W2281113657 hasConcept C126322002 @default.
- W2281113657 hasConcept C141071460 @default.
- W2281113657 hasConcept C143998085 @default.
- W2281113657 hasConcept C2776694085 @default.
- W2281113657 hasConcept C2777063308 @default.
- W2281113657 hasConcept C2777299880 @default.
- W2281113657 hasConcept C2779268555 @default.
- W2281113657 hasConcept C2779338040 @default.
- W2281113657 hasConcept C2780259306 @default.
- W2281113657 hasConcept C2780456651 @default.
- W2281113657 hasConcept C2780775027 @default.
- W2281113657 hasConcept C2780962732 @default.
- W2281113657 hasConcept C526805850 @default.
- W2281113657 hasConcept C71924100 @default.
- W2281113657 hasConcept C90924648 @default.
- W2281113657 hasConceptScore W2281113657C121608353 @default.
- W2281113657 hasConceptScore W2281113657C126322002 @default.
- W2281113657 hasConceptScore W2281113657C141071460 @default.
- W2281113657 hasConceptScore W2281113657C143998085 @default.
- W2281113657 hasConceptScore W2281113657C2776694085 @default.
- W2281113657 hasConceptScore W2281113657C2777063308 @default.
- W2281113657 hasConceptScore W2281113657C2777299880 @default.
- W2281113657 hasConceptScore W2281113657C2779268555 @default.
- W2281113657 hasConceptScore W2281113657C2779338040 @default.
- W2281113657 hasConceptScore W2281113657C2780259306 @default.
- W2281113657 hasConceptScore W2281113657C2780456651 @default.
- W2281113657 hasConceptScore W2281113657C2780775027 @default.
- W2281113657 hasConceptScore W2281113657C2780962732 @default.
- W2281113657 hasConceptScore W2281113657C526805850 @default.
- W2281113657 hasConceptScore W2281113657C71924100 @default.
- W2281113657 hasConceptScore W2281113657C90924648 @default.
- W2281113657 hasIssue "3_suppl" @default.
- W2281113657 hasLocation W22811136571 @default.
- W2281113657 hasOpenAccess W2281113657 @default.
- W2281113657 hasPrimaryLocation W22811136571 @default.
- W2281113657 hasRelatedWork W1970193197 @default.
- W2281113657 hasRelatedWork W2058385450 @default.
- W2281113657 hasRelatedWork W2080692829 @default.
- W2281113657 hasRelatedWork W2123237110 @default.
- W2281113657 hasRelatedWork W2128537370 @default.
- W2281113657 hasRelatedWork W2323399989 @default.
- W2281113657 hasRelatedWork W2347320353 @default.
- W2281113657 hasRelatedWork W2577979650 @default.
- W2281113657 hasRelatedWork W2579548203 @default.
- W2281113657 hasRelatedWork W2766409029 @default.
- W2281113657 hasVolume "32" @default.
- W2281113657 isParatext "false" @default.
- W2281113657 isRetracted "false" @default.
- W2281113657 magId "2281113657" @default.
- W2281113657 workType "article" @default.